Key result
Rheumatic heart disease in pregnancy requires tailored management balancing maternal and fetal risks.
Why the study?
Acute rheumatic fever and rheumatic valvular disease remain prevalent globally and are the most common cause of heart disease in pregnancy, with unclear application of recent management advances in pregnant patients.
How should rheumatic heart disease and associated valvular lesions be managed during pregnancy to optimize maternal and fetal outcomes?
How should rheumatic heart disease and associated valvular lesions be managed during pregnancy to optimize maternal and fetal outcomes?
This review emphasizes the need for individualized management and preconception counseling in women with rheumatic heart disease to mitigate high maternal and fetal risks during pregnancy.
Answers are grounded in this paper and cite their sources.
Highlights need for caution with severe rheumatic valvular lesions in pregnancy; leaves open prospective evaluation of outcomes with modern therapy.
Acute rheumatic fever and rheumatic valvular disease remain prevalent in many parts of the world, and are probably the most common cause of heart disease in pregnancy. Mitral stenosis is the most frequently encountered rheumatic valvular lesion. A variety of pregnancy-associated cardiovascular changes often exacerbate the signs and symptoms of valvular lesions. Pregnancy should not be allowed to proceed, if possible, in patients with uncorrected severe valvular lesions or mechanical heart valves requiring anticoagulation, as maternal and fetal morbidity and mortality are high. For those with milder disease, pregnancy is best undertaken after the valvular lesion has been rectified or stabilised. Recent advances in the management of valvular disease include the use of beta-blockers for patients with mitral stenosis, vasodilators in those with aortic and mitral regurgitation, and percutaneous balloon valvuloplasty for mitral and aortic stenosis. Application of these therapies in the pregnant patient is as yet unclear, and management decision needs to be individualized, weighing the risk and benefit to ensure maternal survival and to promote fetal well-being.
No takes yet. Share an insight, caveat, or question.
Athena Poppas (2002) conducted a review in Rheumatic Heart Disease in Pregnancy. Management of rheumatic heart disease in pregnancy requires individualized decision-making to balance maternal survival and fetal well-being, as the application of recent therapies remains unclear.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: